Axelys

Vega Bioimaging is a company focused on enhancing cancer diagnostics to ensure that patients receive tailored treatments, ultimately improving their survival rates and quality of life. It has developed a novel immunolabeling technology that employs nanobeads of various colors to target specific proteins, leading to more quantitative and precise biopsy analysis. This advanced approach facilitates better stratification of cancer patients and more accurate assessments of their eligibility for precision therapies. The Vega solution comprises three core components: a protein detection kit, a slide digitizing system that seamlessly integrates with existing microscopy platforms, and quantification software powered by artificial intelligence. Through these innovations, Vega Bioimaging aims to provide deeper insights into diseases and support the development of more effective cancer treatments.

ChitogenX Inc is a clinical-stage biotechnology company focused on developing innovative therapeutic technologies for soft tissue repair. The company specializes in creating advanced devices aimed at enhancing the success rates of orthopedic surgeries, particularly in sports medicine. By leveraging its proprietary approaches, ChitogenX seeks to address the challenges associated with tissue repair and improve patient outcomes in orthopedic treatments.